Stockscreener 앱 받기
5.8349
0.93%
0.0549
전일 마감가:
$5.78
열려 있는:
$5.78
하루 거래량:
511.38K
Relative Volume:
0.21
시가총액:
$1.19B
수익:
-
순이익/손실:
$-54.70M
주가수익비율:
-17.68
EPS:
-0.33
순현금흐름:
$-51.36M
1주 성능:
-2.28%
1개월 성능:
-9.56%
6개월 성능:
+126.11%
1년 성능:
+117.67%
1일 변동 폭
$5.73
$5.95
1주일 범위
$5.73
$6.49
52주 변동 폭
$1.89
$7.005
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
SVRA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.835 | 1.18B | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.68 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.88 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
863.39 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.04 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Savara Grants Equity Awards to New Hires as It Advances Rare Lung Drug - mychesco.com
How Investors May Respond To Savara (SVRA) Adding Approval-Linked Hercules Credit To Its Liquidity Toolkit - simplywall.st
Savara Ekes up on Deal with Hercules - Baystreet.ca
Savara secures additional $75m in debt financing for potential drug launch - Investing.com
Savara Enters New Material Definitive Agreement and Obligation - TipRanks
Savara amends loan agreement to access up to $105 million in term loans - Investing.com
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* - Business Wire
Savara (SVRA) Faces Class Action Lawsuit Over Shareholder Losses - Intellectia AI
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CEO Moves: Does Star Equity Holdings Inc have a competitive edgeLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Rare lung drug nears FDA decision as PANTHERx, Savara seal US deal - MSN
Rare Lung Drug Nears FDA Decision as PANTHERx, Savara Seal U.S. Deal - mychesco.com
Savara Secures $75 Million Royalty Deal to Back Potential MOLBREEVI Launch - MSN
FDA clock restarts: Savara refiles MOLBREEVI for rare lung disease - MSN
Day Trade: What is the dividend yield of LIVEJuly 2025 Breakouts & Risk Managed Investment Strategies - baoquankhu1.vn
Aug Opening: Should I trade or invest in Savara Inc2025 Institutional Moves & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Savara Announces New Employment Inducement Grant - Business Wire
What Savara (SVRA)'s Exclusive PANTHERx MOLBREEVI Distribution Deal Means For Shareholders - simplywall.st
Aug Opening: Will Savara Inc benefit from government policyRate Cut & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Value Recap: Can Savara Inc disrupt its industryJobs Report & Weekly Watchlist of Top Performers - baoquankhu1.vn
Savara Highlights Autoimmune PAP Burden in Updated Presentation - TipRanks
Lobbying Update: $30,000 of SAVARA INC. lobbying was just disclosed | SVRA Stock News - Quiver Quantitative
With 37% stake, Savara Inc. (NASDAQ:SVRA) seems to have captured institutional investors' interest - Yahoo Finance
Savara Inc. (NASDAQ:SVRA) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Savara Inc. Announces Equity Awards for New Employees - MSN
Savara Inc. Grants Inducement Awards to New Employees with Stock Options & RSUs - MSN
How big funds are accumulating Savara Inc. (YB4P) stock2025 Price Action Summary & Capital Protection Trade Alerts - Улправда
Why Savara Inc. stock is favored by top institutions2025 Stock Rankings & Growth Focused Entry Reports - ulpravda.ru
How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - Улправда
The Bull Case For Savara (SVRA) Could Change Following Exclusive MOLBREEVI Distribution Deal With PANTHERx - simplywall.st
Market Fear: Will Savara Inc. stock outperform growth indexesMarket Risk Analysis & Smart Swing Trading Alerts - Улправда
How Savara Inc. stock benefits from global expansionJuly 2025 Movers & Fast Gaining Stock Strategy Reports - Улправда
Will Savara Inc. stock outperform growth indexes2025 Market WrapUp & AI Powered Market Trend Analysis - ulpravda.ru
Will Savara Inc. stock outperform tech sector in 20252025 Price Momentum & Daily Price Action Insights - Улправда
How Savara Inc. (YB4P) stock compares with top peersProduct Launch & Technical Confirmation Alerts - Улправда
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com
Savara : Corporate Presentation - MarketScreener
Can Savara Inc. stock beat market expectations this quarterJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance Australia
Will Savara Inc. stock sustain high P E ratiosPortfolio Performance Summary & AI Forecasted Stock Moves - ulpravda.ru
Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - Улправда
Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru
Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn
Will Savara Inc. stock benefit from sector rotation2026 world cup usa national team group stage key players transition play expert forecast insights - ulpravda.ru
Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN
FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo
Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat
Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat
Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn
Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.27%
0.46%
자본화:
|
볼륨(24시간):